FINWIRES · TerminalLIVE
FINWIRES

$IMNM

6 stories mentioning IMNMUpdated 27d ago

Every FINWIRES story that references IMNM, newest first.

Wire

Immunome Says FDA Accepted NDA for Desmoid Tumors Drug

Immunome (IMNM) said Wednesday that the US Food and Drug Administration has accepted its new drug application for varegacestat, intended to treat adults with desmoid tumors.The agency assigned a Prescription Drug User Fee Act target action date of April 28, 2027, the company said.The company said its application was based on a phase-3 trial, which met its primary endpoint of improving progression-free survival compared with a placebo. The trial also met key secondary endpoints, it said.Shares of the company were down more than 5% in Wednesday's premarket activity.Price: $23.08, Change: $-1.31, Percent Change: -5.36%

$IMNM
Insider Trading

Immunome Insider Sold Shares Worth $2,412,522, According to a Recent SEC Filing

Isaac Barchas, Director, on July 06, 2026, sold 100,000 shares in Immunome (IMNM) for $2,412,522. Following the Form 4 filing with the SEC, Barchas has control over a total of 211,763 common shares of the company, with 103,259 shares held directly and 108,504 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1472012/000180834326000007/xslF345X05/form4-07072026_110744.xml

$IMNM
Insider Trading

Immunome Insider Sold Shares Worth $1,244,331, According to a Recent SEC Filing

Robert Lechleider, Chief Medical Officer, on July 02, 2026, sold 55,000 shares in Immunome (IMNM) for $1,244,331. Following the Form 4 filing with the SEC, Lechleider has control over a total of 15,805 common shares of the company, with 15,805 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1472012/000199758426000004/xslF345X05/form4-07072026_090711.xml

$IMNM
Insider Trading

Immunome Insider Sold Shares Worth $1,091,662, According to a Recent SEC Filing

Robert Lechleider, Chief Medical Officer, on June 25, 2026, sold 55,000 shares in Immunome (IMNM) for $1,091,662. Following the Form 4 filing with the SEC, Lechleider has control over a total of 15,805 common shares of the company, with 15,805 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1472012/000199758426000002/xslF345X05/form4-06292026_080646.xml

$IMNM
Insider Trading

Immunome Insider Sold Shares Worth $1,093,800, According to a Recent SEC Filing

Max Rosett, Chief Financial Officer, on June 15, 2026, sold 60,000 shares in Immunome (IMNM) for $1,093,800. Following the Form 4 filing with the SEC, Rosett has control over a total of 54,037 common shares of the company, with 54,037 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1472012/000199407126000004/xslF345X05/form4-06172026_090615.xml

$IMNM
Wire

Immunome Submits Varegacestat NDA Backed by Phase 3 Data

Immunome (IMNM) said Wednesday it has submitted a New Drug Application to the US Food and Drug Administration for varegacestat, an investigational oral treatment for adults with desmoid tumors.The filing is backed by positive Phase 3 RINGSIDE results showing significantly improved progression-free survival versus placebo, with an 84% reduction in the risk of disease progression or death and a 56% objective response rate, the company said.The company added that detailed data from the trial will be presented at the 2026 ASCO Annual Meeting.Shares of Immunome were down 2.7% in Wednesday trading.Price: $23.18, Change: $-0.53, Percent Change: -2.24%

$IMNM

Track with the FINWIRES app suite

FolioX
FolioX
Track IMNM in your portfolio
WheelAI
WheelAI
Analyze IMNM options with the wheel strategy
StockInsider
StockInsider
See market sentiment on IMNM